Company intelligence / Profile preview
Syncromune
Fort Lauderdale, Florida, United Statessyncromune.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Syncromune’s lead programs are in Phase I clinical trials targeting metastatic solid tumors. The company’s SYNC-T and Syncrovax platforms combine partial tumor oncolysis with direct intratumoral delivery of multi-target biologics to synchronize antigen release and immune activation. Early results in mCRPC patients have been described as “powerful,” with a Q2 data presentation planned for their lead program.
- Therapeutic areas
- Oncology
- Modalities
- Intratumoral immunotherapyMulti-target biologic drugsOncolytic therapy (partial oncolysis)Antibody-based therapies (e.g., OX40 antibody)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Eucure Biopharma Co., Ltd. / Biocytogen Pharmaceuticals – exclusive worldwide license agreement for YH002 OX40 antibody and two other active ingredients.
Beyond the preview
Go deeper on Syncromune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syncromune.